Literature DB >> 28606225

[Clinical characteristics and prognostic analysis of children and adolescents over 10 years of age with acute lymphoblastic leukemia].

Jun Wu1, Ai-Dong Lu, Le-Ping Zhang.   

Abstract

OBJECTIVE: To explore the clinical characteristics and prognosis of children and adolescents over 10 years of age with acute lymphoblastic leukemia (ALL).
METHODS: A total of 86 newly diagnosed ALL children and adolescents over 10 years of age (62 cases of B-ALL and 24 cases of T-ALL) were enrolled. Clinical characteristics, therapeutic effect and prognostic factors were retrospectively analyzed. Event-free survival (EFS) and overall survival (OS) rates were estimated by the Kaplan-Meier method. Prognostic factors were evaluated by COX regression analysis.
RESULTS: Of 86 patients, 62 were in medium risk, and 24 in high risk. At diagnosis, 53 patients (62%) had hepatomegaly, 50 patients (58%) had splenomegaly, and 46 patients (54%) had lymphoadenopathy. Twenty-nine patients (34%) showed high leukocyte counts (≥50×109/L) at diagnosis. The karyotype analysis was performed on 78 patients. The percentage of hyperdiploidy was 19% (15 cases), and that of hypodiploidy was 5% (4 cases). Eleven patients (14%) had abnormalities of chromosome structure. Of them, one patient was Philadelphia chromosome-positive, and another patient had the t (1; 19) chromosomal translocation. Three patients (4%) were positive for TEL/AML1, 3 (4%) were positive for E2A/PBX1, 6 were positive for BCR/ABL (7%), and 4 (5%) were positive for SIL/TAL1. During 4 weeks of induction therapy, 85 patients (99%) achieved complete remission (CR). In 86 patients, the 5-year anticipated EFS and OS were (64±6)% and (75±5)% respectively. The 5-year EFS and OS in the medium risk group were significantly higher than those in the high risk group (P<0.05). The 5-year EFS in B-ALL patients was significantly higher than that in T-ALL patients (P<0.05). COX multivariate analysis showed that white blood counts at diagnosis and minimal residual disease (MRD) after induction therapy were independent prognostic factors.
CONCLUSIONS: Children and adolescents with ALL over 10 years of age often have clinical characteristics of unfavorable prognosis. White blood counts at diagnosis and MRD after induction therapy may be important factors for the long-term prognosis.

Entities:  

Mesh:

Year:  2017        PMID: 28606225      PMCID: PMC7390288     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  18 in total

1.  Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands.

Authors:  J M de Bont; B van der Holt; A W Dekker; A van der Does-van den Berg; P Sonneveld; R Pieters
Journal:  Leukemia       Date:  2004-12       Impact factor: 11.528

2.  [Recommendations for diagnosis and treatment of acute lymphoblastic leukemia in childhood (3rd revised version)].

Authors: 
Journal:  Zhonghua Er Ke Za Zhi       Date:  2006-05

3.  Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.

Authors:  William A Wood; Stephanie J Lee; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Karen K Ballen; David K Buchbinder; Jason Dehn; Cesar O Freytes; Hillard M Lazarus; Charles F Lemaistre; Paulette Mehta; David Szwajcer; Steven Joffe; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

4.  Improved prognosis for older adolescents with acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; Deqing Pei; Dario Campana; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Elaine Coustan-Smith; Sima Jeha; Cheng Cheng; Monika L Metzger; Deepa Bhojwani; Hiroto Inaba; Susana C Raimondi; Mihaela Onciu; Scott C Howard; Wing Leung; James R Downing; William E Evans; Mary V Relling
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

5.  Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.

Authors:  Helene Hallböök; Göran Gustafsson; Bengt Smedmyr; Stefan Söderhäll; Mats Heyman
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

6.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.

Authors:  Valentino Conter; Claus R Bartram; Maria Grazia Valsecchi; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Maurizio Aricò; Martin Zimmermann; Georg Mann; Giulio De Rossi; Martin Stanulla; Franco Locatelli; Giuseppe Basso; Felix Niggli; Elena Barisone; Günter Henze; Wolf-Dieter Ludwig; Oskar A Haas; Giovanni Cazzaniga; Rolf Koehler; Daniela Silvestri; Jutta Bradtke; Rosanna Parasole; Rita Beier; Jacques J M van Dongen; Andrea Biondi; Martin Schrappe
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.

Authors:  Nicolas Boissel; Marie-Françoise Auclerc; Véronique Lhéritier; Yves Perel; Xavier Thomas; Thierry Leblanc; Philippe Rousselot; Jean-Michel Cayuela; Jean Gabert; Nathalie Fegueux; Christophe Piguet; Françoise Huguet-Rigal; Christian Berthou; Jean-Michel Boiron; Cécile Pautas; Gérard Michel; Denis Fière; Guy Leverger; Hervé Dombret; André Baruchel
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

8.  Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.

Authors:  Michael J Burke; Nathan Gossai; John E Wagner; Angela R Smith; Veronika Bachanova; Qing Cao; Margaret L MacMillan; Heather S Stefanski; Daniel J Weisdorf; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-06       Impact factor: 5.742

9.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

Authors:  Wendy Stock; Mei La; Ben Sanford; Clara D Bloomfield; James W Vardiman; Paul Gaynon; Richard A Larson; James Nachman
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

10.  Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival.

Authors:  Daniel Willian Lustosa de Sousa; Francisco Valdeci de Almeida Ferreira; Francisco Helder Cavalcante Félix; Marcos Vinicios de Oliveira Lopes
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-14
View more
  1 in total

1.  [Multicenter clinical trial of acute lymphoblastic leukemia in elder children and adolescents].

Authors:  N Zhang; S H Shen; N L Wang; H Li; J W Yang; J P Shao; H Jiang; J Y Tang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.